 SARTORIUS (OTCMKTS:SARTF – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 500 shares,  a decrease of 44.4% from the September 30th total of 900 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 5.0 days. Based on an average trading volume of 100 shares, the short-interest ratio is presently 5.0 days.
SARTORIUS (OTCMKTS:SARTF – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 500 shares,  a decrease of 44.4% from the September 30th total of 900 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 5.0 days. Based on an average trading volume of 100 shares, the short-interest ratio is presently 5.0 days. 
SARTORIUS Price Performance
SARTF opened at $211.46 on Friday. SARTORIUS has a 52-week low of $165.00 and a 52-week high of $243.35. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.95 and a quick ratio of 0.88. The business’s fifty day moving average is $198.36 and its 200-day moving average is $197.59.
SARTORIUS (OTCMKTS:SARTF – Get Free Report) last announced its quarterly earnings data on Thursday, October 16th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. The firm had revenue of $987.65 million for the quarter, compared to the consensus estimate of $972.82 million. SARTORIUS had a net margin of 3.82% and a return on equity of 8.19%.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on SARTF
SARTORIUS Company Profile
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers.
Recommended Stories
- Five stocks we like better than SARTORIUS
- How to Evaluate a Stock Before Buying
- Why Microsoft’s Post-Earnings Dip Is a Buy-the-Pause Moment
- Insider Buying Explained: What Investors Need to Know
- NVIDIA’s Billion-Dollar Bet Puts Nokia Back in the Growth Game
- How to Calculate Stock Profit
- Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations
Receive News & Ratings for SARTORIUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SARTORIUS and related companies with MarketBeat.com's FREE daily email newsletter.

 
						 
						 
						